Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Once this hits the 200 day everyone will love the stock again.
VMDG upward macd crosses on the 30 and 60
VMDG *Break on the Chart* Only 1 million tradeable!
VMDG *Break on the Chart* Only 1 million tradeable!
thats 15% of todays volume was from institutional MM's they could be buys or sell.
We get a nice bounce tommarrow off of .055 no pumping needed.
Over .30 to continue this trend.
VMDG *Only 1 Million Shares Tradedable till the merger is complete*
VMDG *Only 1 Million Shares Tradedable till the merger is complete*
VMDG 2nd upchannel starting *Only 1 Mil shares Tradedable till merger is complete*
VMDG only 1 million of the OS is tradeable for 2 years. Right now its ripe *hint* *hint* for a large loveable group to hit it.
It is a new company with new managment completely unrelated to the old VWKM crew.
It went from .17-.50 on less the 50k today.
*Sigh*
They sold the shell.
pfrenz VMDG will go.
Hows your BKMP coming along. I sold XKEM at .11 cents how bout you?
Posted by: pfrenz
In reply to: skunksyard who wrote msg# 70990 Date:5/27/2006 12:06:11 AM
Post #of 144751
skunks, I owned 160m shares of QBID all @.0001, so I lost 16k. I will make 50-75 times that with BKMP, in @.00023....Wow! You need to get in fist thing Tuesday, you should be able to buy around .0015 if you do it at the bell, if you wait too long it'll be .003 in a hurry! GLTU
VMDG is new company after they bought the shell from VWKM. Are you people stupid? Do some DD for once.
It pretty much says that in the 9/8 PR:
"Effective immediately, John H. Beebe will serve in the dual capacity of Chairman, Chief Executive Officer and President of both corporations until the completion of the proposed merger; resulting from personally acquiring a majority controlling interest in Vision Works Media Group (VMDG) and subsequently accepting the resignation of Vision Works current Chairman & President Ray Jogovich."
VMDG should be a huge play over the next two weeks.
1 mil share float, and a $14 per share aquistion in todays PR.
I know drillbit and yeah we plucked this stock out of the same chat today. It looks just like FHAL before its big run.
The chat is a super secret room and if the name is spoken you are removed *wink*
I have 10k shares at .225 average which I bought today. I see a FHAL .15-1.70 situation happening here.
If this stock didnt have the VWKM stigma it would have rocketed today.
There needs to be a PR that former VWKM managment has no ties to this company in a any way other then transfering the shell.
If we can prove that the stock is worth exponentially more then it is now.
That needs to be in a PR not a messege board posting.
For the sake of Creditabilty, As a CEO please put future public statements into Press Releases. Posting on messege boards only hurts creditability.
They sold the sell. Do some homework.
VWKM was garbage yes VMDG isnt.
They sold the shell.
Yes VWKM were scammers, VMDG is a entirely new company.
Thanks Penny for the correction. VWKM sold the sold to new management. VWKM was notorious scammers VMDG is a new company with new people running it.
VDMG is not affliated with VWKM in any way. VWKM sold the sell in a reverse merger.
VDMG 1.04 Mil float *$14 a share in assets* Front Haul all over again
Post RS Reverse Merger play
VMDG 1.04 Mil float *$14 a share in assets* Front Haul all over again
It was Stockholder11 who posted the fake PR. He has many aliases and he posted it a many places. His comment he copied it from someone else will be his defense in court.
I covered my short from $8 this week at $1.50. Gotta love crap companies.
If you guys honestly believe that putting shares up for sale prevents short selling then you are dumb.
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
AMZB 18 Mil Float Bottomed Chart Huge After Hours News!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
Sep 5, 2006 6:00:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Related Quotes
Last Change % Change
AMZB 0.115
0.00 0.00
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
LC Group
Rick Lutz
(404) 261-1196
Unless Shakerzz buys the Bears, you will never see another superbowl in your life time.
CMKX has a better chance to buy microsoft.
The Insiders especially Howard has told me thru emails, he will maintain a 51% interest in CHDT. So while he can drop a million here and there, its not like hes gonna dump his whole position.
Lucy I think this is heading down to sideways until we get a PR with something new to sink our teeth into.
With .068 being the absolute bottom that could be tested again in a worse case scenrio by the end of the week.
Let the price fall, I dont care I got Buys all the way down.
Yeah he did.
You betcha! You have to be completely stupid to sell CHDT at these levels.
Yes it was a pump and dump when the run to .235 happened.
However nobody who understands this market would ever confuse shakerzz with smart person.
This stock will see another run-up to higher levels in the coming months I can almost promise that.
Now that hes gone the stock will not be easily manipulated.